Poly (ADP-Ribose)
Polymerase (PARP) Inhibitors Market
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
Market Scope: Industry Analysis, Market Size,
Growth, Trends Till 2031
Request Sample Report
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
Market Size and Growth
The Poly (ADP-Ribose) Polymerase (PARP) inhibitors market is experiencing significant growth, driven by increasing cancer cases and advancements in targeted therapies. The market size is anticipated to reach approximately $5.5 billion by 2026, reflecting rising demand for effective treatments, particularly in breast and ovarian cancers, alongside ongoing research and development efforts.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Pfizer
◍ AstraZeneca
◍ Merck & Co
◍ Myriad Genetics
◍ GlaxoSmithKline
◍ Johnson & Johnson
◍ AbbVie
◍ Teva Pharmaceutical Industries
The PARP inhibitors market features key players like Pfizer, AstraZeneca, and Merck & Co, focusing on cancer therapeutics. Companies drive growth through innovation, extensive R&D, and strategic collaborations. For instance, AstraZeneca reported $1.5 billion in sales from its PARP inhibitor, Lynparza, in recent years, highlighting market potential.
Request Sample Report
Market Segmentation
By Application By Product
Ovarian Cancer
Breast Cancer
Fallopian Tube Cancer
Other
Request Sample Report
Talazoparib
Veliparib
Olaparib
Other
Market Growth
Request Sample Report
$ X Billion USD
